Cargando…
Early Bortezomib Therapy for Refractory Anti-NMDA Receptor Encephalitis
Introduction: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an increasingly recognized form of immune-mediated encephalitis. Here we present a case that represents the shortest hospitalization-to-bortezomib treatment timeline (42 days), and we believe that this is reflected in the patien...
Autores principales: | Turnbull, Marion T., Siegel, Jason L., Becker, Tara L., Stephens, Alana J., Lopez-Chiriboga, A. Sebastian, Freeman, William D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118211/ https://www.ncbi.nlm.nih.gov/pubmed/32292386 http://dx.doi.org/10.3389/fneur.2020.00188 |
Ejemplares similares
-
Bortezomib treatment for severe refractory anti‐NMDA receptor encephalitis
por: Shin, Yong‐Won, et al.
Publicado: (2018) -
Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis
por: Ratuszny, Dominica, et al.
Publicado: (2020) -
Psychiatric Presentation of Anti-NMDA Receptor Encephalitis
por: Endres, Dominique, et al.
Publicado: (2019) -
Psychiatric Symptoms of Patients With Anti-NMDA Receptor Encephalitis
por: Wang, Wei, et al.
Publicado: (2020) -
Clinical Study of Autonomic Dysfunction in Patients With Anti-NMDA Receptor Encephalitis
por: Yan, Lulu, et al.
Publicado: (2021)